Last reviewed · How we verify
NCT07194200
Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
Phase 2 trial testing Lactobacillus plantarum in Psoriasis in 184 participants. Currently enrolling.
25 June 2026
Quick facts
| Lead sponsor | Shenzhen People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 184 |
| Start date | 15 December 2025 |
| Primary completion | 25 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Lactobacillus plantarum — full drug profile →
- inactivated Lactobacillus plantarum — full drug profile →
Conditions studied
- Psoriasis — all drugs for Psoriasis →
- Lactobacillus Plantarum — all drugs for Lactobacillus Plantarum →
Sponsor
Shenzhen People's Hospital
Who can join
Adults 16 to 60, any sex, with Psoriasis or Lactobacillus Plantarum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A growing body of evidence indicates that the pathogenesis of psoriasis may be closely linked to skin microbiome dysbiosis. Compared with healthy individuals, the composition and function of the skin microbiota in psoriasis patients exhibit significant alterations5,6. This microbial imbalance is thought to contribute to the initiation and progression of the disease through mechanisms such as triggering abnormal immune responses, exacerbating inflammatory processes, and impairing the skin barrier. In-depth exploration of the interplay between psoriasis and the microbiome not only offers new perspectives for elucidating the disease's pathogenesis but also lays the groundwork for developing innovative microbiota-targeted diagnostic and therapeutic strategies. Thus, identifying novel therapeutic approaches that bridge psoriasis treatment and microbial regulation holds substantial clinical and social value. While existing treatments for psoriasis have made some progress, research specifically focusing on the microbiota-psoriasis relationship remains relatively limited. Investigating the intrinsic connections between microecological balance and psoriasis management, and developing practical improvement strategies, is therefore of crucial practical significance for enhancing skin health and improving quality of life. This study aims to address this research gap and provide a new therapeutic option for individuals with psoriasis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07194200
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lactobacillus plantarum
Trials testing the same drug.
- NCT06808061 — Effects of Lactobacillus Plantarum KABP-51 Probiotic on Body Composition, Microbiome and Mood in Healthy Overweight Adul · NA · completed
- NCT05520073 — A Pilot Study To Evaluate the Effects of Lactobacillus Supplements · NA · completed
- NCT05544942 — GCWB1001 Evaluates the Effectiveness and Safety of Respiratory Health · NA · completed
- NCT05483660 — A Clinical Trial on the Efficacy of Gastric Probiotics in the Treatment of Helicobacter Pylori Infection · Phase 2 · unknown
- NCT04461782 — Interventional Study to Evaluate the Effect of the Oral Administration of L.Plantarum on Vaginal Microbiota · NA · completed
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
- NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
- NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
- NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
- NCT07265284 — A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis · Phase 3 · recruiting
Other Shenzhen People's Hospital trials
Trials by the same sponsor.
- NCT07512050 — Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity · NA · not yet recruiting
- NCT07366255 — Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis · NA · completed
- NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
- NCT07266532 — Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in Obesity · NA · completed
- NCT07203599 — A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07194200 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen People's Hospital
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07194200.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing